镥-177标记的抗前列腺特异性膜抗原抗体与配体治疗转移性去势抵抗性前列腺癌:系统综述与荟萃分析
该系统综述与荟萃分析纳入截至2016年12月的10项研究、共369例转移性去势抵抗性前列腺癌患者,评估镥-177-PSMA治疗的生化反应。合并分析显示68%(95%CI 61-74)患者出现任何PSA下降,37%(95%CI 22-52)患者PSA下降超过50%。作者认为早期结果有前景,但需随机对照试验验证。
要点
- 10项研究共369例mCRPC患者接受镥-177-PSMA治疗,任何PSA下降的合并比例为68%(95%CI 61-74)。
- PSA下降超过50%的合并比例为37%(95%CI 22-52),异质性I²=91.0%(P<0.001)。
- 177Lu-DKZ/I&T亚组PSA下降超过50%的比例更高,但该亚组研究间异质性大。
核心结论
- 本综述提示镥-177-PSMA治疗mCRPC的早期结果有前景,尤其是使用较新开发的放射性配体治疗的患者。
- 总体荟萃分析显示约三分之二的患者出现生化反应。
- 需要随机对照试验来验证其相对于当前全身治疗的有效性并制定理想的治疗方案。
研究设计与样本
- 系统综述与荟萃分析,检索电子数据库截至2016年12月。
- 两名评价员独立提取数据并评估方法学质量。
- 共纳入10项研究,总样本量为369例,其中334例可分析。
- 采用随机效应荟萃分析计算各研究的合并比例,计算I²统计量评估异质性。
- 敏感性分析剔除两项以摘要形式发表的研究,并按化学类型(177Lu-J591/DKZ/I&T)汇总比例。
主要发现
- 334例可分析患者中220例出现任何PSA下降。
- 任何PSA下降的合并比例为68%(95%CI 61-74),I²=39.1%(P=0.11),提示结果间异质性较小。
- PSA下降超过50%的合并比例为37%(95%CI 22-52),I²=91.0%(P<0.001),提示结果间异质性显著。
- 亚组分析中,177Lu-DKZ/I&T亚组PSA下降超过50%的患者比例更高,但该亚组研究间存在大量异质性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要随机对照试验来验证其相对于当前全身治疗的有效性并制定理想的治疗方案。
- 177Lu-DKZ/I&T亚组研究间存在大量异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Promising therapeutic results of the prostate-specific membrane antigen (PSMA) ligand have been shown when labelling with lutetium-177 (177Lu). We performed a systematic review and meta-analysis to assess the therapeutic response of 177Lu-PSMA in the treatment of metastatic castration-resistant prostate cancer (mCRPC). METHODS: A systematic review was conducted using electronic databases up to December 2016. Two reviewers independently extracted data and assessed methodological quality. The main outcome of interest was antitumour biochemical response of 177Lu-PSMA, analysing two measures: 'any PSA decline' and '>50% decline' from baseline. A random-effects meta-analysis was used to calculate the pooled proportion across studies. The I2 statistic was calculated in each case to investigate the extent of heterogeneity across the studies. A sensitivity analysis was conducted removing two studies, which were presented as abstracts and proportions were summarised by chemical type (177Lu-J591/DKZ/I&T). All analyses were conducted using Stata v14. RESULTS: A total of 10 studies were included in the analysis giving a total sample size of 369, 220 (of 334 analysable) experienced any PSA decline. The pooled proportion of patients with any PSA decline was 68% (95% confidence interval (CI): 61-74). The I2 statistic was 39.1% (P=0.11) suggesting minor heterogeneity between results. The pooled proportion of patients with >50% PSA decline was 37% (95% CI: 22-52). The I2 statistic was 91.0% (P<0.001) suggesting substantial heterogeneity between results. On subgroup analysis, a higher proportion of patients in the 177Lu-DKZ/I&T subgroup had a PSA decline >50%, however, it can be seen that the 177Lu-DKZ/I&T subgroup had a substantial amount of heterogeneity across studies. CONCLUSIONS: This review suggests promising early results for the treatment of mCRPC, especially from patients treated with the more recently developed radioligands. Overall, our meta-analysis showed that approximately two-thirds of patients had a biochemical response. Randomised-controlled trials would be necessary to verify its effectiveness against current systemic therapies and create an ideal treatment protocol.
引用
- Calopedos RJS, Chalasani V, Asher R, et al. Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2017. PMID: 28440324. doi:10.1038/pcan.2017.23
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。